Description |
UNIBO will participate in the recruitment of the following SARS-CoV-2 and non-SARS-CoV-2 fragile populations: HIV positive, solid organ transplant recipients, hematopoietic stem cell transplant recipients and solid cancer.
CONTRAST is an observational cohort study, with a retrospective phase (2015-2020) and a prospective phase (2021-2025) with a minimum follow-up expected for each patient of 1 year. Patients will be studied longitudinally to define the ""net state of immunosuppression"" of each patient to be correlated with the prevalence of SARS-CoV-2 infection, the course of infection in the short, medium and long term, and the immune response to following a SARS-CoV-2 infection or vaccine. |